Indian Pharmacopoeia Commission
Why in news?
IPC signed three major Memorandums of Understanding (MoUs) in Nagaland on November 27, 2025
Recent MoUs
- IPC signed three major Memorandums of Understanding (MoUs) in Nagaland on November 27, 2025, with the Nagaland Medical Council, Nagaland State Drugs Control Administration (NSDCA), and Nagaland State Pharmacy Council.
- These agreements aim to promote the use of Indian Pharmacopoeia Reference Substances in drug testing, enhance pharmacovigilance and materiovigilance activities, and advance patient safety across the state.
- Earlier in September 2025, IPC also signed an MoU with the UP Pharmacy Council to promote rational use of medicines through the National Formulary of India.
About Indian Pharmacopoeia Commission (IPC)
- Indian Pharmacopoeia Commission is an autonomous institution under the Ministry of Health and Family Welfare, Government of India.
- Established in 2005 and fully operational from January 1, 2009, to set and update standards for drugs manufactured, sold, and consumed in India.
- Publishes the Indian Pharmacopoeia (IP), the official book of standards for drug identity, purity, and strength, complying with the Drugs and Cosmetics Act, 1940.
- Regularly updates IP monographs and publishes the National Formulary of India (NFI) to promote rational use of generic medicines.
- Provides IP Reference Substances (IPRS) as fingerprints for drug identification and purity testing.
- Oversees programs like Pharmacovigilance Programme of India (PvPI) and Materiovigilance Programme of India (MvPI) for drug safety monitoring.
- Member of the Pharmacopoeial Discussion Group (PDG) since 2023, aiding global harmonization of pharmaceutical standards.
- Has a three-tier structure: General Body, Governing Body, Scientific Body, supported by IPC Secretariat and Indian Pharmacopoeia Laboratory (IPL).
Download Pdf
